Association between ALK tyrosine kinase inhibitor and the risk of interstitial lung disease and pneumonitis in non-small cell lung cancer patients: a systematic review.
[BACKGROUND] This study aims to investigate the association between anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) and the risks of interstitial lung disease (ILD) and pneumonitis in
- 95% CI 0.00 to 0.02
- OR 8.87
- 연구 설계 meta-analysis
APA
Sun S, Zhang R, et al. (2026). Association between ALK tyrosine kinase inhibitor and the risk of interstitial lung disease and pneumonitis in non-small cell lung cancer patients: a systematic review.. BMC cancer, 26(1), 277. https://doi.org/10.1186/s12885-026-15612-3
MLA
Sun S, et al.. "Association between ALK tyrosine kinase inhibitor and the risk of interstitial lung disease and pneumonitis in non-small cell lung cancer patients: a systematic review.." BMC cancer, vol. 26, no. 1, 2026, pp. 277.
PMID
41578213
Abstract
[BACKGROUND] This study aims to investigate the association between anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) and the risks of interstitial lung disease (ILD) and pneumonitis in patients with non-small cell lung cancer (NSCLC).
[METHODS] We systematically searched PubMed, Embase, Cochrane Central Register of Controlled Trials for randomized controlled trials (RCTs) reporting ILD or pneumonitis events, from inception to April 2024. Pairwise and network meta-analyses were performed. Outcomes were overall/serious ILD and pneumonitis.
[RESULTS] A total of 14 RCTs involving 3859 participants were included. Results showed that ALK-TKIs significantly increased the risks of both overall ILD (RD = 0.01, 95%CI: 0.00 to 0.02, 0.048) and overall pneumonitis (RD = 0.01, 95%CI: 0.00 to 0.02, 0.039) compared to chemotherapy, while no significant difference existed in the risks of both serious ILD (RD = 0.01, 95%CI: -0.00 to 0.02, 0.130) and serious pneumonitis (RD = 0.01, 95%CI: -0.00 to 0.02, 0.109) between ALK-TKIs and chemotherapy. In the network meta-analysis (NMA), brigatinib was associated with significantly higher risks of both overall ILD and overall pneumonitis compared to crizotinib (OR = 8.87, 95%CI: 1.07 to 73.29; OR = 3.43, 95%CI: 1.00 to 11.71, respectively), alectinib (OR = 12.78, 95%CI: 1.56 to 104.98; OR = 6.09, 95%CI:1.57 to 23.68, respectively) and ceritinib (OR = 32.50, 95%CI: 1.05 to 1005.95; OR = 21.88, 95%CI: 1.78 to 268.53, respectively). Furthermore, the NMA revealed that brigatinib was associated with a significantly higher risk of serious pneumonitis compared to ceritinib (OR = 27.26, 95%CI: 1.33 to 558.33).
[CONCLUSIONS] ALK-TKIs increase the risks of both ILD and pneumonitis in NSCLC patients, with brigatinib posing the highest probability among ALK-TKIs.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-026-15612-3.
[METHODS] We systematically searched PubMed, Embase, Cochrane Central Register of Controlled Trials for randomized controlled trials (RCTs) reporting ILD or pneumonitis events, from inception to April 2024. Pairwise and network meta-analyses were performed. Outcomes were overall/serious ILD and pneumonitis.
[RESULTS] A total of 14 RCTs involving 3859 participants were included. Results showed that ALK-TKIs significantly increased the risks of both overall ILD (RD = 0.01, 95%CI: 0.00 to 0.02, 0.048) and overall pneumonitis (RD = 0.01, 95%CI: 0.00 to 0.02, 0.039) compared to chemotherapy, while no significant difference existed in the risks of both serious ILD (RD = 0.01, 95%CI: -0.00 to 0.02, 0.130) and serious pneumonitis (RD = 0.01, 95%CI: -0.00 to 0.02, 0.109) between ALK-TKIs and chemotherapy. In the network meta-analysis (NMA), brigatinib was associated with significantly higher risks of both overall ILD and overall pneumonitis compared to crizotinib (OR = 8.87, 95%CI: 1.07 to 73.29; OR = 3.43, 95%CI: 1.00 to 11.71, respectively), alectinib (OR = 12.78, 95%CI: 1.56 to 104.98; OR = 6.09, 95%CI:1.57 to 23.68, respectively) and ceritinib (OR = 32.50, 95%CI: 1.05 to 1005.95; OR = 21.88, 95%CI: 1.78 to 268.53, respectively). Furthermore, the NMA revealed that brigatinib was associated with a significantly higher risk of serious pneumonitis compared to ceritinib (OR = 27.26, 95%CI: 1.33 to 558.33).
[CONCLUSIONS] ALK-TKIs increase the risks of both ILD and pneumonitis in NSCLC patients, with brigatinib posing the highest probability among ALK-TKIs.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-026-15612-3.
같은 제1저자의 인용 많은 논문 (5)
- The gut microbiome in colorectal anastomotic leakage: from mechanisms to precision.
- A review on ethnobotanical uses, geographical distribution, phytochemistry, quality control and pharmacology of L. plants distributed in the northeastern region of China.
- PGM5 - AS1 regulates ferroptosis - Mediated gastric cancer cell behavior via ERK signaling pathway.
- Multicenter study provides radiomic and biological insights into neoadjuvant chemotherapy response and prognosis in luminal breast cancer.
- Research Progress of Nanodelivery Platforms in the Diagnosis and Treatment of Esophageal Cancer.